Securities code: 300871 securities abbreviation: Hvsen Biotechnology Co.Ltd(300871) Announcement No.: 2022-006 convertible bond Code: 123132 convertible bond abbreviation: Huisheng convertible bond
Hvsen Biotechnology Co.Ltd(300871)
Announcement on the appointment of senior managers
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
In accordance with the relevant provisions of the securities law of the people’s Republic of China, the company law of the people’s Republic of China, the guidelines for self regulatory supervision of listed companies on Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on GEM and the articles of association, Hvsen Biotechnology Co.Ltd(300871) (hereinafter referred to as “the company”) convened the 22nd Meeting of the second board of directors on January 21, 2022, The meeting deliberated and adopted the proposal on the appointment of senior managers of the company, and agreed to appoint Mr. Li Shuo as the deputy general manager of the company. The term of office starts from the date of deliberation and approval by the board of directors to the date of expiration of the second board of directors.
Upon the nomination of the general manager of the company, the nomination committee of the board of directors reviewed the qualifications of the candidates for senior management and considered that Mr. Li Shuo met the qualifications of senior management, had relevant work experience and was competent for the work employed. The independent directors of the company expressed unanimous independent opinions on the appointment of senior managers by the board of directors. See the appendix of the announcement for the resume of Mr. Li Shuo.
It is hereby announced.
Hvsen Biotechnology Co.Ltd(300871) board of directors January 22, 2022 Annex: resume of senior managers
Li Shuo, male, born in 1980, Chinese nationality, doctor, senior engineer, majoring in biomedical engineering, without overseas permanent residency. He joined the company in October 2012 and is now the general manager of the company’s R & D division. Director of Hubei animal health products bioengineering technology research center, executive deputy director of Hubei veterinary medicine engineering technology research center, Hubei industry professor (Wuhan University of science and Technology), Graduate industry supervisor of Huazhong Agricultural University, and selected into Wuhan Huanghe talent program; As the main completion person of the project, he has completed one national 863 project, one major national new drug creation project, two national innovation fund projects, 8 provincial and ministerial scientific research projects, and more than 10 school enterprise joint development projects; He has published 9 research papers (including 4 SCI papers), applied for 13 invention patents (9 of which have been authorized), and won one second prize of technological invention in Hubei Province.
Mr. Li Shuo directly holds 0.02% of the company’s shares and has no associated relationship with other shareholders, actual controllers, other directors, supervisors and senior managers holding more than 5% of the company’s shares; Not punished by the CSRC and other relevant departments or the stock exchange; There are no circumstances specified in article 3.2.3 of the guidelines for self discipline supervision of listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of GEM listed companies; There is no case of being included in the list of dishonest persons to be executed.
